ELV Q1 Deep Dive: Carelon Expansion and Margin Trends in Focus as Guidance Reaffirmed

Health insurance provider Elevance Health (NYSE:EVH) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 13.4% year on year to $49.78 billion. Its non-GAAP profit of $8.84 per share was 1.4% below analysts’ consensus estimates.

Is now the time to buy ELV? Find out in our full research report (it’s free).

StockStory’s Take

Elevance Health began 2025 with results that exceeded Wall Street’s expectations, driven by momentum in its Carelon platform, higher premium yields, and disciplined cost management. Management credited strong growth in Carelon’s pharmacy and services businesses, robust retention in Medicare Advantage, and targeted commercial engagement as primary drivers of the quarter. CEO Gail Boudreaux emphasized the company’s strategy to simplify care and reduce administrative burden, highlighting initiatives like HealthOS integration and value-based care expansion. The team noted that investments in digital platforms and recent acquisitions, including CareBridge, are delivering operational benefits and supporting the company’s broader whole-health approach.

Looking ahead, Elevance Health’s guidance is shaped by stable trends in membership retention, ongoing Medicaid rate negotiations, and continued expansion of Carelon’s risk-based and pharmacy services. Management expects the shift in Medicare Part D seasonality and ongoing integration of recent acquisitions to influence earnings cadence throughout the year. CFO Mark Kaye stated, “We continue to expect more than 60% of adjusted earnings per share to be realized in the first half of the year.” The company is closely monitoring utilization patterns, Medicaid rate updates, and ACA membership stabilization as key factors that could impact its ability to deliver on full-year earnings targets.

Key Insights from Management’s Remarks

Management attributed first quarter performance to expanding Carelon capabilities, digital health platform adoption, and disciplined margin management despite elevated utilization trends.

• Carelon growth drives diversification: Carelon’s pharmacy and services segments experienced notable expansion, particularly through new contracts in post-acute and behavioral health. External sales to health plan clients—including Blues plans—and recent acquisitions such as CareBridge contributed to increased reach and recurring revenue.
• Digital health platform scaling: HealthOS, Elevance’s digital clinical integration platform, now supports over 88,000 providers and 1,200 organizations. Management cited its ability to streamline prior authorizations and deliver real-time clinical insights as a competitive differentiator that enhances provider relationships and operational efficiency.
• Medicaid rate alignment progress: The company made advances aligning Medicaid rates with higher member acuity, noting that April adjustments met expectations and discussions for July are underway. Management highlighted the importance of constructive state partnerships for long-term margin improvement and cost coverage.
• Medicare Advantage retention and value-based care: Elevated retention rates and targeted growth in Medicare Advantage support margin stability. The company is expanding its value-based oncology care model, which has shown reductions in inpatient admissions and improved adherence to treatment protocols, into the Medicare population.
• Administrative simplification initiatives: Elevance eliminated prior authorization requirements for over 400 outpatient procedures for high-performing providers, aiming to reduce administrative complexity and improve access to care. This forms part of a broader effort to rebuild trust and enhance member and provider experiences.

Drivers of Future Performance

Elevance Health’s outlook is shaped by ongoing Medicaid rate negotiations, Carelon segment expansion, and evolving utilization patterns across key government and commercial markets.

• Medicaid rate updates and cost trends: Management is focused on securing actuarially sound Medicaid rates to offset elevated member acuity and utilization. Early year rate adjustments were in line with expectations, and upcoming July renewals—covering about one-third of members—will be critical for margin stabilization in the second half of the year.
• Carelon external growth and integration: Continued growth in Carelon service offerings, notably in specialty pharmacy and post-acute care, is expected to drive both internal synergies and external revenue. Integration of recent acquisitions, like CareBridge, will be crucial for delivering scalable home-based and behavioral health services.
• ACA and Medicare membership dynamics: Stabilization of Individual ACA membership, following a short-term attrition due to lower effectuation rates, and disciplined Medicare Advantage growth strategies are expected to support full-year earnings. Management is attentive to changing member risk profiles and benefit design to maintain profitability.

Catalysts in Upcoming Quarters

In future quarters, our team will be watching (1) the outcome of July Medicaid rate negotiations and resulting margin impact, (2) the pace and profitability of Carelon’s external services adoption—especially in pharmacy and behavioral health, and (3) stabilization of ACA membership following recent attrition. Progress on integrating acquired platforms and further administrative streamlining will also be key performance indicators.

Elevance Health currently trades at $301.96, down from $345.20 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

Trump’s April 2024 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.